Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ameriprise Financial

Blackrock Inc

CNH Industrial NV

Garmin

Infosys

Interpublic Group of Companies

KLA-Tencor

T. Rowe Price Group

Taiwan Semiconductor Manufacturing

United Microelectronics

Vedanta Limited

Releasing two top August stocks from the MDA Growth and Dividend Breakout portfolio and two top samples from prior portfolios. Long-term dividend portfolios have a 1-year average weighted gain of +27.2%. The best gain is from the May 2020 portfolio, +82.1%.

V&M Breakouts: Top Growth And Dividend Stocks For August 2021

AbbVie

Merck

Novo Nordisk

Novartis

Pfizer

Roche Holding AG

The Wall Street firm put big drugmakers' R&D programs through five different tests.

Here Are the Winners of Cowen's Big Pharma R&D Showdown

Apple

Advanced Micro Devices

Fastly

Block

Vaxart

Walgreens

Major benchmarks kicked off the month of August this week, and with it came bouts of volatility.

Volatility Plagues Wall Street During First Week of August

SAN FRANCISCO and SUZHOU, China, Aug. 5, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, and Eli Lilly and Company (NYSE: LLY) today announced new and updated data from the ORIENT-11 study demonstrating a sustained survival benefit of sintilimab in combination with pemetrexed and platinum chemotherapy in the first-line treatment of patients with nonsquamous non-small cell lung cancer. In addition, biomarker results from the trial provide important insights for patients with high major histocompatibility complex (MHC) class-II expression.

Updated Overall Survival Data and Biomarker Results from Sintilimab ORIENT-11 Study in First-Line Nonsquamous Non-Small Cell Lung Cancer Published in the Journal of Thoracic Oncology

The stock price of ​Eli Lilly has seen a rise of nearly 10% over the last twenty-one trading days, and it is also up a solid 55% year-to-date. The company recently announced its Q2 results, with revenues topping but earnings falling short of the street estimates.

Here's Why Eli Lilly Stock May Continue To See Higher Levels

Plus your investment would be worth nearly three times its original value.

If You Invested $24,370 in This Top Stock 5 Years Ago, You'd Be Making $1,000 in Dividends This Year

Alibaba

DuPont de Nemours

PepsiCo

The Dow Jones Industrial Average closed at 35,116.40 on Tuesday with a gain of 278.24 points or 0.80%. The S&P 500 closed at 4,423.15 for a gain of 35.99 points or 0.82%.

US Stocks Close With Gains Tuesday

Eli Lilly and Co. (NYSE:LLY) shares popped nearly 4% on Tuesday despite missing analyst expectations on earnings. The company reported its most recent quarterly results before the market opened, positing an EPS of $1.87, slightly lower than the consensus Street estimate of $1.89 earnings per share.

Eli Lilly shares edge higher despite Q2 earnings miss: should you buy or sell LLY?

Eli Lilly and Company (LLY) CEO David Ricks on Q2 2021 Results - Earnings Call Transcript

Accenture Plc

Automatic Data Processing

CME Group

Costco

Cisco Systems

General Dynamics

Home Depot

Honeywell

Intel

Johnson & Johnson

Lockheed Martin

Mastercard

Medtronic

Microsoft

NIKE

Procter & Gamble

Stryker

Texas Instruments

Union Pacific

Visa

Walmart

This article updates one published by David Van Knapp in June 2020.

The Highest Quality Dividend Growth Stocks

Eli Lilly (LLY) reports mixed second-quarter results and ttightens 2021 sales forecast. Stock down in pre-market trading.

Eli Lilly (LLY) Q2 Earnings Miss, Sales Beat, Stock Down

Eli Lilly & Co (NYSE: LLY) said on Tuesday its profit in the fiscal second quarter came in weaker than expected. Revenue, however, topped Wall Street estimates in Q2.

Eli Lilly CEO explains why profit missed estimates in fiscal Q2

The shares of Eli Lilly And Co (NYSE:LLY) are up 4.1% at $256.69, after the company reported second-quarter earnings of $1.87 per share, which fell slightly below analysts' estimates.

Eli Lilly Stock Hits New Highs Despite Earnings Miss

Lilly (LLY) delivered earnings and revenue surprises of -1.06% and 2.62%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) Lags Q2 Earnings Estimates

Shares of Eli Lilly (NYSE:LLY) decreased 1.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 1.06% over the past year to $1.87, which missed the estimate of $1.92.

Eli Lilly: Q2 Earnings Insights

Eli Lilly And Co (NYSE: LLY) posted Q2 sales of $6.74 billion, beating the consensus of $6.65 billion and an increase of 23% Y/Y,  Higher sales were driven by a 22% increase in volume and a 3% to favorable foreign exchange rate impact, partially offset lower realized prices.

Lilly Stock Slips On Mixed Bag Q2 Earnings, Cuts FY21 Sales Outlook For COVID-19 Therapies

Shares of Eli Lilly & Co. fell 1.4% in premarket trading Tuesday after the drug maker missed second-quarter profit expectations while revenue beat, as gross margin as a percentage of revenue fell due primarily to an excess inventory charge related to COVID-19 antibodies. Net income slipped to $1.39 billion, or $1.53 a share, from $1.41 billion, or $1.55 a share, in the year-ago period.

Eli Lilly's stock falls after profit comes up short of expectations, while revenue beat

Drugmaker Eli Lilly and Co reported a 2% drop in quarterly profit on Tuesday, hurt by lower demand for its COVID-19 therapies due to vaccine rollouts in the United States.

Drugmaker Eli Lilly reports 2% drop in quarterly profit

INDIANAPOLIS, Aug. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2021. "We delivered strong performance this quarter, with volume-driven growth across our core business and most major geographies.

Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance

Incyte

INDIANAPOLIS, Aug. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID-19 on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) who received baricitinib plus standard of care were 46 percent less likely to die by Day 28 compared to patients who received placebo plus standard of care (nominal p-value=0.0296; hazard ratio [HR] [95% CI] = 0.54 [0.31, 0.96]; analysis not adjusted for multiplicity).

Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation

News for Eli Lilly Stock (LLY)